Skip to content

Royal Philips

US · PHG #821 by market cap Listed 1970
24.09 -0.06 -0.25%
Live - 5344 symbols - heartbeat 557s ago · 2026-10-08 07:42
Pre-market 23.92 -0.71%
After-hours 24.10 +0.04%
Overnight 23.76 -1.37%
Market cap
23.55B
P/B
1.84
EPS
1.04
Reader sentiment Are you bullish or bearish on PHG?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 1.84 In line with history 53rd percentile
5-year average 1.71 · #48 of 126 in Medical Devices
P/E ratio 18.75 Expensive vs history 72nd percentile
5-year average 8.97 · forward 17.68 · #10 of 38 in Medical Devices
P/S ratio 1.20 In line with history 48th percentile
5-year average 1.14 · forward 1.23 · #35 of 137 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Royal Philips (PHG) 23.55B 18.72 1.84 4.12%
Abbott Laboratories (ABT) 170.84B 31.95 3.34 2.47%
Medtronic (MDT) 109.38B 21.06 2.18 3.33%
Stryker Corp (SYK) 105.64B 28.54 4.40 1.26%
Boston Scientific (BSX) 60.26B 16.83 2.42 0.00%
Edwards Lifesciences (EW) 49.44B 49.87 4.66 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★★★ Fair value32.04 Economic moatWide UncertaintyMedium

Trading 33.0% below Morningstar's fair value estimate.

Fair value

Koninklijke Philips NV receives a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 24% discount to our quantitative fair value estimate of $32.04 per share; however, some caution is warranted due to this estimate's medium uncertainty rating.

The company's valuation metrics strengthen our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to market value ratio of 1.3 ranks in the top 40% compared with global peers. While highly leveraged firms can be risky, they can also be highly rewarding. This company's high enterprise value relative to its market value suggests that wise investments will yield outsize returns for investors. We believe this is a sign that shares could be cheap.

The company's profitability is an additional encouraging factor. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 7.7%, a core component of profitability, ranks in the top 30% compared with global peers. This suggests that it is generating substantial earnings relative to its share price, which further promotes our favorable price/fair value ratio.

Economic moat

The company's excess returns on capital and superb profitability, which could persist for decades or more, warrant a wide economic moat rating. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-10-08 07:42:34 · For reference only, not investment advice and not tailored to your situation.